BiondVax Announces Fourth Quarter and Full Year 2020 Financial Results and Provides News Updates

BiondVax Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Updates

Following the balance sheet date, in February 2021 the Company completed a follow-on offering on Nasdaq, providing total gross proceeds of approximately $13.8 million and net proceeds after fees and discounts of approximately $12.8 million. As of May 12, 2021, the Company had cash and cash equivalents of NIS 46 million (approximately $14 million). As of December 31, 2020, BiondVax had cash and cash equivalents of NIS 9.4 million ($2.9 million) compared to NIS 72.4 million as of December 31, 2019. The complete financial results are available in the Company’s annual report on Form 20-F for the year ended December 31, 2020, to be filed with the Securities and Exchange Commission. A summary is included in the tables below.

 Full Year 2020 Financial Summary  Total operating expenses for the quarter were NIS 12.3 million ($3.2 million) compared with NIS 45.7 million for the fourth quarter of 2019.
R&D expenses for the quarter amounted to NIS 7.8 million ($2.4 million) compared with NIS 37.6 million for the fourth quarter of 2019.

Total operating expenses for the year were NIS 68.2 million ($21.2 million) offset by other income of NIS 75.8 million ($23.4 million) due to the revaluation of the EIB loan compared with NIS 78.3 million in 2019.
R&D expenses for the year amounted to NIS 51.4 million ($16 million) compared with NIS 68.6 million in 2019. Results are in New Israel Shekels (NIS) and convenience translation to US$ is provided using the exchange rate of 3.215 (NIS/US$), the rate as of the close of business on December 31, 2020.  

Management Comment Mr. Amir Reichman, BiondVax’s CEO, commented, “My team and the Board are actively engaged in pursuing opportunities to diversify our pipeline of assets in light of our new mission. BiondVax’s vaccine development, manufacturing, and clinical trial experience, combined with our people’s deep industry experience and our highly advanced GMP vaccine manufacturing facility provide us with an incredible untapped potential that I aim to realize over the coming years. I look forward to leading BiondVax to the next level.” Appointed a new CEO: Mr. Amir Reichman began serving as BiondVax’s CEO on a full-time basis March 2, 2021, taking over from Dr. Ron Babecoff, who has continued to serve BiondVax as a senior advisor to ensure a smooth transition. Most recently, Reichman held senior leadership positions at the GSK Vaccine headquarters in Belgium, including Head of Global Vaccines Engineering Core Technologies and Asset Management, and Senior Director Global GSK Vaccines Supply Chain.
New Mission: As described in his March 23, 2021 CEO Letter to Shareholders, Reichman explained that while previously BiondVax had been a one product company, going forward the Company is implementing a strategy to diversify its pipeline of products towards a new mission: To help build a healthier and happier world by developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses.
Financing: In February 2021, BiondVax completed a follow-on offering on Nasdaq with total gross proceeds of approximately $13.8 million to strengthen the Company’s balance sheet. These additional funds will be used to support ongoing operating expenses and implementation of the new corporate mission and strategy. BiondVax continues to remain in close contact with its main creditor, the European Investment Bank (EIB), to whom the Company has a €24 million outstanding debt. The EIB is supportive of the Company’s ongoing efforts to reposition itself and to date has not indicated an intent to recall the loan.
Assets: The Company’s highly advanced GMP vaccine manufacturing facility in Jerusalem is being maintained by its highly experienced staff as it seeks to expand its product asset pipeline in the coming quarters.

Following the October 23, 2020 announcement that the Phase 3 trial of M–001, our universal influenza vaccine candidate, did not meet its efficacy endpoints, BiondVax implemented the following actions: Recent Corporate Update

The News Highlights

  • BiondVax Announces Fourth Quarter and Full Year 2020 Financial Results and Provides News Updates
  • Check the latest News news updates and information about business, finance and more.
Disclaimer: If you need to edit or update this news from compsmag then kindly contact us Learn more

For Latest News Follow us on Google News


Latest Headlines
  • Show all
  • Trending News
  • Popular By week
OSHA Announces COVID-19 Temporary Emergency Standard for Health Workers – Occupational Health and Safety

OSHA Announces COVID-19 Temporary Emergency Standard for Health Workers – Occupational Health and Safety

Source We have got a lot to talk about on this episode of the podcast. In the last week, there has been a lot of movement from both federal OSHA and state ...
The Outer Worlds 2 will not be available on PS5 or PS4

The Outer Worlds 2 will not be available on PS5 or PS4

However, with Microsoft’s acquisition of developer Obsidian, the sequel will no longer release on Sony’s suite of systems. While it’s clearly still extremely ...
FINRA seeks comments on expanding short interest reporting requirements – finance and banks

FINRA seeks comments on expanding short interest reporting requirements – finance and banks

Additionally, FINRA is considering the adoption of a new rule that would improve its short sale reporting program by requiring that clearing firms submit, ...
Redfall is an Xbox exclusive vampire game. Coming from the developers of Dishonored

Redfall is an Xbox exclusive vampire game. Coming from the developers of Dishonored

During Microsoft and Bethesda’s recent E3 broadcast, Dishonored developer Arkane Studios revealed its newest project, announcing a multiplayer vampire game ...
'I want a solution to this problem' |  Business owner in downtown Austin reacts to implementation of camping ban

CDC Grants $38 Million to State: Money Must Be Used to Reduce Pandemic Health Disparities | Coronavirus

The CDC provided grantees with concrete examples for how they might spend the grant dollars. “This funding represents a significant investment in health ...
Future Apple Watches May Feature Blood Glucose and Body Temperature Sensors

Future Apple Watches May Feature Blood Glucose and Body Temperature Sensors

But the years ahead could bring more substantial improvements for Apple’s wearable. Top of the list is a new blood glucose monitoring feature, which could ...
PS5 new stock information, Track on Twitter, Walmart, Target and more

According to the new leak, Playstation exclusives such as God of War, Ghost of Tsushima, Bloodborne, and others will be coming to PC

Leaks suggest Playstation exclusives like God of War, Ghost of Tsushima, Bloodborne, etc coming to PC in coming years Summer 2022 God of War (2018) While it ...
Ventura County Public Health awaits state reopening on Tuesday

Ventura County Public Health awaits state reopening on Tuesday

“We are now going to do business as usual for communal disease control and prevention at the county level,” said Vargas. “We will continue to do contact ...
STARFIELD, HALO, and Game Pass are among the Xbox games on display

STARFIELD, HALO, and Game Pass are among the Xbox games on display

At the start of the showcase, game director Todd Howard presented a cinematic teaser for Starfield, Bethesda’s next big Western RPG exclusive to the Xbox ...
Harrow Health Announces Aggregate Price of $17.5 Million

Harrow Health Announces Aggregate Price of $17.5 Million

About Harrow HealthHarrow Health, Inc. (NASDAQ: HROW) is an ophthalmic-focused healthcare company. The Company owns and operates ImprimisRx, one of the ...
Show next
Compsmag - Latest News from tech, business and health
Logo